Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WALTHAM, MASS., DEC. 03, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THE COMPANY WILL HOST A VIRTUAL KEY OPINION LEADER (KOL) EVENT TO DISCUSS UPDATED DATA FROM THE ALLOHA PHASE 1 TRIAL BEING PRESENTED AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION AND THE FUTURE MARKET OPPORTUNITY FOR ITS HEME PROGRAM. THE VIRTUAL EVENT WILL TAKE PLACE ON MONDAY, DECEMBER 8, AT 8:00 A.M. ET.

TSCAN THERAPEUTICS TO HOST VIRTUAL KOL EVENT TO DISCUSS CLINICAL UPDATES FROM THE ALLOHA PHASE 1 TRIAL AND FUTURE MARKET OPPORTUNITIES

REACHED AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 FOLLOWING PRODUCTIVE END OF PHASE 1 MEETING DATA FROM ALLOHA  PHASE 1 HEME TRIAL TO BE PRESENTED AT THE 67 TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION MADE THE STRATEGIC DECISION TO PRIORITIZE CLINICAL DEVELOPMENT OF THE HEME PROGRAM AND INITIATE PRECLINICAL DEVELOPMENT OF IN VIVO-ENGINEERED TCR-T FOR SOLID TUMORS CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2027 WALTHAM, MASS., NOV. 12, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE.

TSCAN THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WALTHAM, MASS., NOV. 05, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE BEING HELD AT THE INTERCONTINENTAL BOSTON IN BOSTON, MA ON WEDNESDAY, NOVEMBER 12, 2025 AT 10:00 A.M. EASTERN TIME.

TSCAN THERAPEUTICS TO PARTICIPATE IN THE GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE

POSITIVE END OF PHASE I MEETING AND AGREEMENT REACHED WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 DOSED FIRST SOLID TUMOR PATIENTS WITH MULTIPLEX TCR-T THERAPY; PAUSED FURTHER ENROLLMENT TO PRIORITIZE HEME DEVELOPMENT; REITERATES PLANNED DATA READOUT IN Q1 2026 ENACTED ~30% WORKFORCE REDUCTION TO FOCUS CLINICAL DEVELOPMENT ON HEME PROGRAM AND INITIATE PRE-CLINICAL DEVELOPMENT OF IN VIVO-ENGINEERED TCR-T FOR SOLID TUMORS STRATEGIC PRIORITIZATION EXTENDS CASH RUNWAY INTO H2 2027 CONFERENCE CALL AND WEBCAST SCHEDULED FOR MONDAY, NOVEMBER 3, 8:00 A.M. EASTERN TIME WALTHAM, MASS.

TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 AND ANNOUNCES STRATEGIC PRIORITIZATION TO ADVANCE TSC-101 AND EXTEND CASH RUNWAY INTO H2 2027

HIGHLIGHTS DISCOVERY OF NOVEL TARGETS IN T CELL-DRIVEN AUTOIMMUNE DISORDERS; INITIAL FINDINGS TO BE PRESENTED AT THE ACR CONVERGENCE 2025 HIGHLIGHTS DISCOVERY OF NOVEL TARGETS IN T CELL-DRIVEN AUTOIMMUNE DISORDERS; INITIAL FINDINGS TO BE PRESENTED AT THE ACR CONVERGENCE 2025

TSCAN THERAPEUTICS ANNOUNCES UPCOMING ORAL AND POSTER PRESENTATIONS AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025

WALTHAM, MASS., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCEDTHAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

TSCAN THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

TWO-YEAR RELAPSE DATA FROM ALLOHA PHASE 1 HEME TRIAL TO BE PRESENTED BY END OF YEAR EXPECTS TO DOSE FIRST SOLID TUMOR PATIENTS WITH MULTIPLEX TCR-T IN THE THIRD QUARTER OF 2025 CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES CONTINUE TO FUND OPERATIONS INTO THE FIRST QUARTER OF 2027 WALTHAM, MASS., AUG. 12, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

TSCAN THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WALTHAM, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE BEING HELD AT THE MARRIOTT MARQUIS IN NEW YORK, NY ON WEDNESDAY, JUNE 4, 2025 AT 4:55 P.M. EASTERN TIME.

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

UPDATES FROM THE PLEXI-T SOLID TUMOR AND ALLOHA HEME PHASE 1 CLINICAL TRIALS ANTICIPATED BY END OF YEAR ON-TRACK TO FILE IND APPLICATION FOR TSC-102-A0301 (CD45; HLA-A*03:01) TO FDA IN THE SECOND HALF OF THE YEAR APPOINTED COMMERCIAL LEADER STEPHEN CAMIOLO AS SENIOR VICE PRESIDENT, MARKET ACCESS CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES CONTINUE TO FUND OPERATIONS INTO THE FIRST QUARTER OF 2027 WALTHAM, MASS., MAY 06, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE.

TSCAN THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WALTHAM, MASS., APRIL 28, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCEDTHE ACCEPTANCE OF AN ABSTRACT FOR POSTER PRESENTATION AT THE UPCOMING AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) 28ANNUAL MEETING BEING HELD MAY 13  17 IN NEW ORLEANS, LA AS WELL AS VIRTUALLY.

TScan Therapeutics, Inc.

TCRX

Price

Financial Reports

No items found.

Press Releases

TScan Therapeutics, Inc.

TCRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TCRX